SunGlowInnovations

Evidence summary

Historical records cover approximately 25 patients. Available documentation describes local tissue changes and both local and serious adverse events.

Where the historical records came from

The brochure summarizes records from approximately 25 patients. Most were treated in Germany, with other records from China, Mexico and Italy. The material comes from prior physician-led care and includes symptoms, photographs, imaging and some pathology findings.

Lesion changes, symptoms and pathology

In one case of an ulcerated breast tumor with bleeding, the record describes cessation of bleeding, pain relief and necrosis in most of the tumor. In a different breast cancer case, surgical pathology found no malignancy in the treated specimen while a deeper, uninjected mass remained viable. The pathology finding therefore refers to the sampled treatment zone.

Imaging and follow-up records

The brochure describes a metastatic squamous cell carcinoma lymph node in the neck that developed necrosis and later showed avascular fibrosis. In a case of recurrent breast cancer, two lesions showed necrosis and healing. The record describes local control lasting more than 14 months for the lesions in that case.

Adverse events recorded in the historical material

The brochure records injection-site pain, transient fever and drainage or expulsion of dead tissue. The records also include a superficial chemical burn associated with needle-track reflux, suppurative inflammation in a treated zone, and one episode of serious infection and sepsis after suspected perforation of a necrotic bowel tumor.

Historical human case records

The historical collection covers about 25 people. This table summarizes the ten detailed cases in IND Module 2.5, Table 3-1, including one benign tumor (H8), and adds the separate serious adverse event from Table 4-1.

Scroll sideways to read all columns.

CaseTumorLocal responseSafety recordFollow-up
H1 Ulcerated breast cancer with active bleedingBleeding stopped during treatment. Pain later decreased and most of the tumor became necrotic.No other event was recorded beyond the local necrotic changes.Day-7 photographs showed central necrosis and collapse. Subsequent records describe wound improvement.
H2 Invasive ductal breast carcinomaSurgical pathology found no malignancy in the treated specimen. Viable cancer was found deeper outside the treated area and in additional specimens.Suppurative inflammation, necrosis and ulceration in the treated specimen.Further excision was performed and final margins were reported negative.
H3 Prostate cancerImaging recorded a volume change from about 17.81 cm³ to 5.51 cm³. PSA also decreased.No adverse event reported.Imaging comparison at about two weeks.
H4 Peritoneal carcinomatosisThe physician documented disappearance of treated lesions on follow-up and reduced inflammation.No adverse event reported.Physician follow-up was recorded without a specified interval in the case table.
H5 Recurrent nasopharyngeal carcinomaThe record describes improvements in breathing, pain, sleep and appetite, followed by expulsion of necrotic tissue.Expulsion of necrotic tissue was recorded. No systemic adverse event was recorded.Follow-up CT reported no definite soft-tissue mass.
H6 Recurrent cervical cancerCT, ultrasound and MRI at different assessments documented a smaller lesion and extensive necrosis.Passage of a small necrotic fragment was recorded. No other adverse event was recorded.Serial imaging and an observation about 24 hours after repeat treatment.
H7 Metastatic squamous cell carcinoma in a cervical lymph nodeCentral necrosis and minor drainage were documented on days 10–15.Minor drainage was recorded. Fever or infection was not observed.At day 40, the skin had healed and residual tissue was avascular and fibrotic.
H8 Benign neck tumorThe record describes lesion necrosis and local resolution.No adverse event recorded.The collection cleared in about 10 days. Later photographs showed lesion resolution and scabbing.
H9 Multiple liver metastasesEarly ultrasound documented extensive necrotic change. The main lesion was reported to decrease from 34 mm to 14 mm.No adverse event recorded.Post-repeat imaging documented continuing liquefactive necrosis.
H10 Locally recurrent invasive ductal breast carcinomaTwo treated lesions showed necrosis and healing. Local control of the treated sites was documented for more than 14 months.Superficial second-degree chemical burn associated with needle-track reflux, which healed.Follow-up CT recorded no definite mass in the treated area and new nodes outside the treated field.
AE-01 Colorectal cancer · separate safety recordThe record describes tumor necrosis followed by suspected perforation.Serious infection progressed to sepsis and the sponsor assessed it as probably related to treatment.Hospital treatment was reported. The final outcome was not reported to the sponsor.

Source

Investigator’s Brochure v1.0 §§6.1–6.3, Table 6-1 and Figures 6-1–6-6 · IND Module 2.5, Tables 3-1 and 4-1